Actively Recruiting
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
Led by M.D. Anderson Cancer Center · Updated on 2025-12-26
2000
Participants Needed
1
Research Sites
702 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
CONDITIONS
Official Title
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients over the age of 18
- Diagnosis of gynecologic mesonephric-like adenocarcinoma, mesonephric adenocarcinoma, mesonephric carcinosarcoma, or mesonephric-like carcinosarcomas
- Ability to speak and/or read English or Spanish for patients who provide consent
You will not qualify if you...
- Patients with other subtypes of endometrial adenocarcinomas (EACs)
- Patients considered cognitively impaired, as determined by the need for a Legally Authorized Representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
J
Jeffrey How, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here